IceCure Medical Ltd.最新临床研究数据显示，其冷冻消融技术在四年随访期内展现出卓越的肿瘤控制效果。针对直径不超过3厘米的肿瘤患者群体，无复发存活率高达89.4%；而整体研究人群的无复发存活率同样表现强劲，达到83.9%。
该结果凸显了冷冻消融技术对于小尺寸肿瘤的长期疗效优势。相较于传统治疗方式，这项微创技术不仅为患者提供了更优的临床结局，同时显著降低了治疗过程中的创伤风险。研究数据进一步验证了该技术在不同肿瘤尺寸患者群体中保持稳定疗效的能力。
随着医学界对微创治疗需求的持续增长，这些长期随访数据为冷冻消融技术的临床应用提供了有力支撑。值得注意的是，83.9%的整体无复发率表明该技术具备广泛的适用性，为更多肿瘤患者提供了新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.